小柯机器人

美国默克公司Antoni Ribas研究组报道了经派姆单抗治疗的实体瘤患者在疾病进展后的肿瘤动力学。这一研究成果于2023年9月11日发表在国际顶尖学术期刊《癌细胞》上。

数据来自799例黑色素瘤(n = 176)、非小细胞肺癌(NSCLC;n = 146)，胃癌(GC;n = 87)，头颈部鳞状细胞癌(HNSCC;n = 112)，透明细胞肾细胞癌(ccRCC;n = 51)，尿路上皮癌(UC;n = 227)纳入进展期治疗(TBP)。根据RECIST v1.1，接受派姆单抗治疗的患者已超过确诊的进展性疾病(PD)。一部分患者在进展后病变直径总和减少30%(黑色素瘤24.4%，NSCLC 11.6%， GC 12.6%， HNSCC 8.9%， ccRCC 15.7%， UC 13.2%)。

大多数患者在进展后表现出稳定的靶病变动态(黑色素瘤，64.8%;非小细胞肺癌,72.6%;GC 69.0%， HNSCC 75.9%， ccRCC 72.5%， UC 75.3%)。派姆单抗在超过RECIST v1.1进展的亚组患者中产生有意义的疗效。

据悉，虽然许多患者接受了TBP，但这些患者的临床获益程度和持续时间尚未得到充分量化。

附：英文原文

Pembrolizumab generates meaningful efficacy in a subset of patients treated beyond RECIST v1.1 progression.

Title: Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progression

Author: Brian G. Topp, Madhav Channavazzala, Kapil Mayawala, Dinesh P. De Alwis, Eric Rubin, Alexandra Snyder, Jedd D. Wolchok, Antoni Ribas

Issue&Volume: 2023/09/11

Abstract: While many patients are treated beyond progression (TBP), the magnitude and duration of clinical benefit in these patients have not been fully quantified. Data from 799 patients with melanoma (n = 176), non-small cell lung cancer (NSCLC; n = 146), gastric cancer (GC; n = 87), head and neck squamous cell carcinoma (HNSCC; n = 112), clear-cell renal cell carcinoma (ccRCC; n = 51), and urothelial carcinoma (UC; n = 227) TBP were included. Patients had received pembrolizumab beyond confirmed progressive disease (PD) per RECIST v1.1. A subset of patients displays a 30% reduction in the sum of lesion diameters in the post-progression period (melanoma 24.4%, NSCLC 11.6%, 12.6% GC, 8.9% HNSCC, 15.7% ccRCC, and 13.2% UC). Most patients show stable target lesion dynamics in the post-progression period (melanoma, 64.8%; NSCLC, 72.6%; GC, 69.0%, 75.9% HNSCC, 72.5% ccRCC, 75.3% UC). Pembrolizumab generates meaningful efficacy in a subset of patients treated beyond RECIST v1.1 progression.

DOI: 10.1016/j.ccell.2023.08.004

Source: https://www.cell.com/cancer-cell/fulltext/S1535-6108(23)00280-5

Cancer Cell：《癌细胞》，创刊于2002年。隶属于细胞出版社，最新IF：38.585
官方网址：https://www.cell.com/cancer-cell/home
投稿链接：https://www.editorialmanager.com/cancer-cell/default.aspx